Related posters
(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors
anti-hVISTA against poorly immunogenic tumors
April 10, 2021
Background
- VISTA (V-domain Ig Suppressor of T cell Activation) is a unique B7 family member, mainly expressed on myeloid cells, neutrophils, NK cells and Treg
- VISTA is highly expressed on MDSC and Treg in the TME and play an important role in immune modulation
- VISTA is a negative regulator that directly suppresses T-cell activation and proliferation
- High VISTA expression correlates with poor survival in cancer patients
- VISTA is a unique Immune checkpoint inhibitor for tumor immunotherapy
Conclusion
- 107 fully human ScFv anti-VISTA antibodies were generated and analyzed
- Kineta’s anti-VISTA lead antibody is highly specific
- Kineta’s anti-VISTA lead antibody activates monocytes, and this activation is NK dependent
- Kineta’s anti-VISTA lead antibody reverse MDSC suppression of T cells
- Kineta’s anti-human VISTA lead antibody induces strong anti-tumor response as a single agent or in combo-therapies with anti-PDL1 or anti-CTLA4 in different hard to treat tumor models
- KVA 12.1 is our lead antibody for IND enabling studies.
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
Scientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Customer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Collaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate